TREATMENT WITH ANTI-TIGIT ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS
The present invention relates to the treatment of esophageal cancer, e.g., esophageal squamous cell carcinoma (ESCC) (e.g., advanced ESCC (e.g., unresectable, locally advanced, recurrent, and/or metastatic ESCC)). More specifically, the invention pertains to the treatment of patients having esophage...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
26.04.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to the treatment of esophageal cancer, e.g., esophageal squamous cell carcinoma (ESCC) (e.g., advanced ESCC (e.g., unresectable, locally advanced, recurrent, and/or metastatic ESCC)). More specifically, the invention pertains to the treatment of patients having esophageal cancer by administering a combination of an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody and a programmed death-1 (PD-1) axis binding antagonist. |
---|---|
Bibliography: | Application Number: EP20210706122 |